ArticleScientific reports2016
Development and characterisation of highly antibiotic resistant Bartonella bacilliformis mutants.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Plasmid-mediated azithromycin resistance in non-typhoidal Salmonella recovered from human infections.The Journal of antimicrobial chemotherapy · 2024Article
- Unusual and Unconsidered Mechanisms of Bacterial Resilience and Resistance to Quinolones.Life (Basel, Switzerland) · 2024Review
- Single-nucleotide polymorphisms in ialB, gltA and rpoB genes of Bartonella bacilliformis isolated from patients in endemic Peruvian regions.PLoS neglected tropical diseases · 2023Article
- Advancements in understanding the molecular and immune mechanisms ofFrontiers in microbiology · 2023Review
- Multiple Mechanisms Confer Resistance to Azithromycin inMicrobiology spectrum · 2022Article
- Link Between Antibiotic Persistence and Antibiotic Resistance in Bacterial Pathogens.Frontiers in cellular and infection microbiology · 2022Review
- Adaptive Resistance Mutations at Suprainhibitory Concentrations Independent of SOS Mutagenesis.Molecular biology and evolution · 2021Article
- Molecular Characterization of Fluoroquinolone-ResistantPathogens (Basel, Switzerland) · 2021Article
- From Genome to Drugs: New Approaches in Antimicrobial Discovery.Frontiers in pharmacology · 2021Review
- Cell cycle regulated DNA methyltransferase: fluorescent tracking of a DNA strand-separation mechanism and identification of the responsible protein motif.Nucleic acids research · 2020Article
- Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics.Biosensors · 2020Article
- Carrion's Disease: the Sound of Silence.Clinical microbiology reviews · 2018Review
- Carrion's disease: an eradicable illness?Infectious diseases of poverty · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective was to develop and characterise in vitro Bartonella bacilliformis antibiotic resistant mutants. Three B. bacilliformis strains were plated 35 or 40 times with azithromycin, chloramphenicol, ciprofloxacin or rifampicin discs. Resistance-stability was assessed performing 5 serial passages without antibiotic pressure. MICs were determined with/without Phe-Arg-β-Napthylamide and artesunate. Target alterations were screened in the 23S rRNA, rplD, rplV, gyrA, gyrB, parC, parE and rpoB genes. Chloramphenicol and ciprofloxacin resistance were the most difficult and easiest (>37.3 and 10.6 passages) to be selected, respectively. All mutants but one selected with chloramphenicol achieved high resistance levels. All rifampicin, one azithromycin and one ciprofloxacin mutants did not totally revert when cultured without antibiotic pressure. Azithromycin resistance was related to L4 substitutions Gln-66 → Lys or Gly-70 → Arg; L4 deletion Δ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.